Enveric Biosciences (ENVB) Other Operating Expenses (2015 - 2026)
Enveric Biosciences (ENVB) posted Other Operating Expenses of $37240.0 for Q1 2026, down 5.69% sequentially from $39485.0 in Q4 2025, and down 54.04% YoY from $81024.0 in Q1 2025.
Enveric Biosciences (ENVB) Other Operating Expenses (2015 - 2026) Analysis & Trends
Enveric Biosciences has reported Other Operating Expenses for 12 years, with the latest figure at $37240.0 in Q1 2026.
- Quarterly Other Operating Expenses fell 54.04% year-over-year to $37240.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157074.0 (down 52.85% YoY) and the FY2025 annual result came in at $200858.0, down 40.48% from the prior year.
- Other Operating Expenses retreated to $37240.0 in Q1 2026 per ENVB's latest filing, from $39485.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $7.5 million in Q4 2022 and troughed at $37240.0 in Q1 2026.
- A 5-year average of $511831.8 and a median of $84779.0 in 2024 frame the typical range for Other Operating Expenses.
- The widest YoY moves for Other Operating Expenses: up 24.86% in 2023, down 98.88% in 2023.
- Over 5 years, Other Operating Expenses stood at $7.5 million in 2022, then tumbled by 98.88% to $84682.0 in 2023, then decreased by 2.59% to $82487.0 in 2024, then sank by 52.13% to $39485.0 in 2025, then dropped by 5.69% to $37240.0 in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $37240.0, $39485.0, and $40369.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,240.00 |
| Dec 31, 2025 | 39,485.00 |
| Sep 30, 2025 | 40,369.00 |
| Jun 30, 2025 | 39,980.00 |
| Mar 31, 2025 | 81,024.00 |
| Dec 31, 2024 | 82,487.00 |
| Sep 30, 2024 | 84,814.00 |
| Jun 30, 2024 | 84,779.00 |
| Mar 31, 2024 | 85,409.00 |
| Dec 31, 2023 | 84,682.00 |
| Sep 30, 2023 | 86,296.00 |
| Jun 30, 2023 | 86,518.00 |
| Mar 31, 2023 | 86,486.00 |
| Dec 31, 2022 | 7.54 Mn |
| Sep 30, 2022 | 86,646.00 |
| Jun 30, 2022 | 85,502.00 |
| Mar 31, 2022 | 69,265.00 |
| Dec 31, 2021 | 38.85 Mn |
| Sep 30, 2021 | 173,696.00 |
| Jun 30, 2021 | 174,019.00 |